Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ATOMO DIAGNOSTICS LIMITED Investor Presentation 2021

Mar 16, 2021

64440_rns_2021-03-16_6a46b266-7e3a-4fde-9d07-d0183c3e15ce.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

ASX Announcement

17 March 2021

==> picture [133 x 39] intentionally omitted <==

Atomo to present at NWR Virtual Investor Conference

SYDNEY Australia Wednesday, 17 March 2021 – Australian rapid blood test company Atomo Diagnostics Limited (ASX: AT1) ( Atomo ) is pleased to announce it will present at the NWR Virtual Investor Conference to be held on Thursday, 18 March 2021.

The Company invites shareholders and investors to see Atomo Diagnostics CEO John Kelly and CFO Will Souter present an update at 12:30pm (AEDT) on 18 March 2021.

Event : NWR Virtual Investor Conference

Presenting : Mr John Kelly (CEO, Atomo Diagnostics) and Mr Will Souter (CFO, Atomo Diagnostics)

Time : Thursday, 18 March 2021, 12:30pm (AEDT) for 25 minutes

Investors are invited to submit questions prior to the event to:

[email protected]

Investors can register online to view the presentation here: https://us02web.zoom.us/webinar/register/WN_vWcRVTYnT1qtWEXW-7O1GA

For further information on the conference click here: https://nwrconference.webflow.io/

For more information, please contact:

Jane Lowe John Kelly IR Department Atomo Diagnostics [email protected] [email protected] Phone: +61 411 117 774 Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

Atomo Diagnostics Limited ACN 142 925 684 Level 2, 701 – 703 Parramatta Road, Leichhardt NSW 2040

==> picture [133 x 39] intentionally omitted <==

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com.

Atomo Diagnostics Limited ACN 142 925 684 Level 2, 701 – 703 Parramatta Road, Leichhardt NSW 2040